Journal of Endocrinological Investigation

, Volume 10, Issue 3, pp 277–282 | Cite as

Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine

  • I. Halperin
  • M. D. Rodriguez
  • C. Cardenal
  • R. Casamitjana
  • M. J. Martinez Osaba
  • V. Lienas
  • E. Vilardell


Long-acting im bromocriptine was administered to 7 patients with pituitary macroadenomas (4 acromegalics, 1 Nelson’s syndrome and 2 prolactinomas), with good tolerance except during the first 24 h. During a 42-day period hormonal, CT-scan and visual field variations were followed. In acromegalics HGH decrease was not evident, except in some isolated sample. In Nelson’s syndrome ACTH showed a 94% fall on day 14, even though a spontaneous oscillation cannot be ruled out, and recovery took place from day 21 on. PRL remained undetectable in both. In prolactinomas, PRL suffered a great decrease (91.8% and 96.3% on days 21 and 28 respectively) and remained well below its initial values up to the end of the study, in spite of partial recovery. In these 2 patients CT-scan evidenced shrinkage of tumor mass, which was not observed in the remaining 5 cases. Visual fields did not improve in the 2 cases initially affected (Nelson’s syndrome and 1 prolactinoma). Long-acting bromocriptine seems to have the same therapeutic uses of the oral form with the possible advantage of a better tolerance of full initial doses.


Pituitary adenomas growth hormone prolactin corticotropin long-acting bromocriptine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thorner M.O., Besser G.M. Bromocriptine treatment of hyperprolactinaemic hypogonadism. Acta Endocrinol. (Kbh.) 88(Suppl. 216): 131, 1978.Google Scholar
  2. 2.
    Bergh T., Nillius S.J., Wide L. Bromocriptine treatment of 42 hyperprolactinemic women with secondary amenorrhoea. Acta Endocrinol. (Kbh.) 88: 435, 1978.Google Scholar
  3. 3.
    Bergh T., Nillius S.J., Wide L. Hyperprolactinemic amenorrhoea-Results of treatment with bromocriptine. Acta Endocrinol. (Kbh.) 88(Suppl. 216): 147, 1978.Google Scholar
  4. 4.
    Thorner M.O., Schran H.F., Evans W.S., Rogol A.D., Morris J.L., MacLeod R.M. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J. Clin. Endocrinol. Metab. 50: 1026, 1980.PubMedCrossRefGoogle Scholar
  5. 5.
    Liuzzi A., Dallabonzana D., Oppizzi G., Verde G.G., Cozzi R., Chiodini P., Luccarelli G. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N. Engl. J. Med. 313: 656, 1985.PubMedCrossRefGoogle Scholar
  6. 6.
    Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang R.J., Jaffe R., Joplin G., Robbins R.J., Tyson J., Thorner M.O., Bromocriptine Study Group. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicentric study. J. Clin. Endocrinol. Metab. 60: 698, 1985.PubMedCrossRefGoogle Scholar
  7. 7.
    Clayton R.N., Webb J., Heath D.A., Dunn P.J.S., Rolfe E.B., Hockley A.D. Dramatic and rapid shrinkage of a massive invasive prolactinoma with bromocriptine: A case report. Clin. Endocrinol. (Oxf.) 22: 573, 1985.CrossRefGoogle Scholar
  8. 8.
    Bassetti M., Spada A., Pezzo G., Giannattasio G. Bromocriptine treatment reduces the cell size in human macroprolactinomas: A morphometric study. J. Clin. Endocrinol. Metab. 58: 268, 1984.PubMedCrossRefGoogle Scholar
  9. 9.
    Belforte L., Camanni F., Chiodini G., Liuzzi A., Massara F., Molinatti G.M., Müller E.E., Silvestrini F. Long-term treatment with 2-Br-α-ergocryptine in acromegaly. Acta Endocrinol. (Kbh.) 85: 235, 1977.Google Scholar
  10. 10.
    Eskildsen P.C., Svendsen P.A., Vang L., Nerup J. Long-term treatment of acromegaly with bromocriptine. Acta Endocrinol. (Kbh.) 87: 687, 1978.Google Scholar
  11. 11.
    Kennedy A.L., Sheridan B., Montgomery D.A.D. ACTH and cortisol response to bromocriptine and results of long-term therapy in Cushing’s disease. Acta Endocrinol. (Kbh.) 89: 461, 1978.Google Scholar
  12. 12.
    Benker G., Hackenberg K., Hamburger B., Reinwein D. Effects of growth hormone release-inhibiting hormone and bromocriptine (CB 154) in states of abnormal pituitary-adrenal function. Clin. Endocrinol. (Oxf.) 5: 187, 1976.CrossRefGoogle Scholar
  13. 13.
    Landolt A.M., Del Pozo E., Hayek J. Injectable bromocriptine to treat acute, oestrogen-induced swelling of invasive prolactinoma. Lancet 2: 111, 1981.Google Scholar
  14. 14.
    Gen M., Uozumi T., Ohta M., Ito A., Kajiwara H., Mori S. Necrotic changes in prolactinomas after long term administration of bromocriptine. J. Clin. Endocrinol. Metab. 59: 463, 1984.PubMedCrossRefGoogle Scholar
  15. 15.
    Tucker H. StG., Grubb S.R., Wigand J.P., Taylon A., Lankford H.V., Blackard W., Becker D.P. Galactorrhea-amenorrhea syndrome: follow-up of forty-five patients after pituitary tumor removal. Ann. Intern. Med. 94: 302, 1981.PubMedCrossRefGoogle Scholar
  16. 16.
    Serri O., Rasio E., Beauregard H., Hardy J., Somma M. Recurence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N. Engl. J. Med. 309: 280, 1983.PubMedCrossRefGoogle Scholar
  17. 17.
    Nabarro J.D.N. Pituitary prolactinomas. Clin. Endocrinol. (Oxf.) 17: 129, 1982.CrossRefGoogle Scholar
  18. 18.
    Del Pozo E., Schlüter K., Nüesch E., Rosenthaler J., Kerp L. Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone. Eur. J. Clin. Pharmacol. 29: 615, 1986.PubMedCrossRefGoogle Scholar
  19. 19.
    Grossman A., Ross R., Wass J.A.H., Besser G.M. Depot-bromocriptine treatment for prolactinomas and acromegaly. Clin. Endocrinol. (Oxf.) 24: 231, 1986.CrossRefGoogle Scholar
  20. 20.
    Werner S., Hall K., Sjöberg H.E. Bromocriptine therapy in patients with acromegaly: effects on growth hormone, somatomedin A and prolactin. Acta Endocrinol. (Kbh.) 88: 199, 1978.Google Scholar
  21. 21.
    Clayton R.N., Vrionides Y., Lynch S.S., Butt W.R., London D.R. Response of acromegaly to long term bromocriptine therapy: a biochemical and clinical assessment. Acta Endocrinol. (Kbh.) 89: 469, 1978.Google Scholar
  22. 22.
    Wass J.A.H., Clemmons D.R., Underwood L.E., Barrow I., Besser G.M., Van Wyk J.J. Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Clin. Endocrinol.(Oxf) 17: 369, 1982.CrossRefGoogle Scholar
  23. 23.
    Moses A.C., Molitch M.E., Sawin C.T., Jackson I., Biller B.J., Furlanetto R., Reichlin S. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C. J. Clin. Endocrinol. Metab. 53: 753, 1981.Google Scholar
  24. 24.
    Lamberts S.W.J., Timmermans H.A.T., De Jong F.H., Birkenhäger J.C. The role of dopaminergic depletion in the pathogenesis of Cushing’s disease and the possible consequences for medical therapy. Clin. Endocrinol. (Oxf.) 7: 185, 1977.CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1987

Authors and Affiliations

  • I. Halperin
    • 1
  • M. D. Rodriguez
    • 1
  • C. Cardenal
    • 1
  • R. Casamitjana
    • 1
  • M. J. Martinez Osaba
    • 1
  • V. Lienas
    • 1
  • E. Vilardell
    • 1
  1. 1.Endocrinology Department, Hormonal Laboratory, Radiology DepartmentHospital Clinic i ProvincialBarcelonaSpain

Personalised recommendations